Literature DB >> 1733833

Apolipoprotein E phenotypes and hyperlipidemia in patients under maintenance hemodialysis.

G Feussner1, S Wey, J Bommer, D Deppermann, P Grützmacher, R Ziegler.   

Abstract

Apolipoprotein E phenotypes and gene frequencies were determined in 560 patients receiving long-term hemodialysis. In addition, fasting plasma lipid- and apolipoprotein-concentrations were evaluated in 245 of these individuals. The distribution of the three major apolipoprotein E alleles (epsilon 4, epsilon 3, and epsilon 2) and that of the six common apolipoprotein E phenotypes (E4/4, E3/3, E2/2, E4/2, E4/3, and E3/2) in the dialysis group was nearly identical to that of healthy controls. Patients with the apolipoprotein E phenotypes E2/2, E4/4 and E4/3 (comprising 24% of the whole group) had higher mean plasma cholesterol- and triglyceride-concentrations than those with the apolipoprotein E phenotypes E3/3 and E3/2 (72% of the whole group). Thus, the genetic polymorphism of apolipoprotein E may contribute to the individual risk of accelerated atherosclerosis in patients under maintenance hemodialysis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733833     DOI: 10.1007/bf00197265

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  48 in total

1.  On estimating the relation between blood group and disease.

Authors:  B WOOLF
Journal:  Ann Hum Genet       Date:  1955-06       Impact factor: 1.670

2.  Lipoprotein spectrum analysis of uremic patients maintained on chronic hemodialysis.

Authors:  J M Felts; B Zacherle; G Childress
Journal:  Clin Chim Acta       Date:  1979-04-02       Impact factor: 3.786

3.  Gel isoelectric focusing method for specific diagnosis of familial hyperlipoproteinemia type 3.

Authors:  G R Warnick; C Mayfield; J J Albers; W R Hazzard
Journal:  Clin Chem       Date:  1979-02       Impact factor: 8.327

4.  Effects of plasmapheresis on familial type III hyperlipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus.

Authors:  K Suzaki; S Kobori; S Ueno; M Uehara; T Kayashima; H Takeda; S Fukuda; K Takahashi; N Nakamura; H Uzawa
Journal:  Atherosclerosis       Date:  1990-01       Impact factor: 5.162

5.  Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism.

Authors:  E Boerwinkle; G Utermann
Journal:  Am J Hum Genet       Date:  1988-01       Impact factor: 11.025

Review 6.  Cardiovascular disease in patients on chronic hemodialytic therapy.

Authors:  S Scharf; J Wexler; R E Longnecker; M D Blaufox
Journal:  Prog Cardiovasc Dis       Date:  1980 Mar-Apr       Impact factor: 8.194

7.  Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype.

Authors:  Y A Kesäniemi; C Ehnholm; T A Miettinen
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

Review 8.  Apolipoprotein E polymorphism in health and disease.

Authors:  G Utermann
Journal:  Am Heart J       Date:  1987-02       Impact factor: 4.749

9.  Increased frequency of the apolipoprotein E-4 isoform in male subjects with multifactorial hypercholesterolemia.

Authors:  T P Leren; A L Børresen; K Berg; I Hjermann; P Leren
Journal:  Clin Genet       Date:  1985-05       Impact factor: 4.438

10.  Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows.

Authors:  W J Schneider; P T Kovanen; M S Brown; J L Goldstein; G Utermann; W Weber; R J Havel; L Kotite; J P Kane; T L Innerarity; R W Mahley
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

View more
  7 in total

1.  Apolipoprotein E polymorphism in hemodialyzed patients and healthy controls.

Authors:  Jaroslav A Hubacek; Silvie Bloudickova; Ruzena Kubinova; Hynek Pikhart; Ondrej Viklicky; Martin Bobak
Journal:  Biochem Genet       Date:  2009-06-30       Impact factor: 1.890

2.  Some developments on the affected-pedigree-member method of linkage analysis.

Authors:  P J Ward
Journal:  Am J Hum Genet       Date:  1993-06       Impact factor: 11.025

3.  Apolipoprotein E and kidney function in older adults.

Authors:  Rebecca Kurnik Seshasai; Ronit Katz; Ian H de Boer; David Siscovick; Michael G Shlipak; Dena E Rifkin; Mark J Sarnak
Journal:  Clin Nephrol       Date:  2012-09       Impact factor: 0.975

4.  Association of apoE gene polymorphisms with lipid metabolism in renal diseases.

Authors:  Tianbiao Zhou; Hongyan Li; Hongzhen Zhong; Zhiqing Zhong; Shujun Lin
Journal:  Afr Health Sci       Date:  2020-09       Impact factor: 0.927

5.  Association of APOE polymorphism with chronic kidney disease in a nationally representative sample: a Third National Health and Nutrition Examination Survey (NHANES III) Genetic Study.

Authors:  Audrey Y Chu; Rulan S Parekh; Brad C Astor; Josef Coresh; Yvette Berthier-Schaad; Michael W Smith; Alan R Shuldiner; Wen Hong L Kao
Journal:  BMC Med Genet       Date:  2009-10-23       Impact factor: 2.103

Review 6.  Apolipoprotein E gene variants on the risk of end stage renal disease.

Authors:  Cheng Xue; Wei Nie; Dan Tang; Lujiang Yi; Changlin Mei
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

7.  Apolipoprotein E polymorphism modulation of asymmetric dimethylarginine in hypertensive patients is determined by renal function.

Authors:  Mauro Sergio Martins Marrocos; Andrei Alkmin Teixeira; Beata Marie Quinto; Silmara de Melo Carmona; Mariana Kuniyoshi; Cassio Jose Rodrigues; Maria Aparecida Dalboni; Silvia Manfredi; Maria Eugênia Canziani; Marcelo Costa Batista
Journal:  Lipids Health Dis       Date:  2016-01-20       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.